ADC Development Services for Non-Hodgkin Lymphoma (NHL) Research

Currently, patients with relapsed or refractory non-Hodgkin lymphoma (NHL) have an unfavorable prognosis due to few treatment options. Fortunately, several ADCs have been reported to be potential effective for NHL treatment. Antibody-drug conjugates (ADCs) are one of the fastest-growing classes of oncology therapeutics, which directly target tumour-associated cell-surface antigens and provide targeted drug delivery with improving potency while reducing non-specific cytotoxic effects.

Now Creative Biolabs provides a comprehensive set of ADC development services for the NHL-targeting drug discovery, our professional scientists have extensive experience in antibody production, synthetic chemistry, and bio-conjugation and are committed to providing high-quality services to promote the development of innovative cancer treatments.

Introduction of NHL

NHL is a type of cancer that begins in lymphocytes, which is the seventh most prevalent form of cancer in the United States according to the National Cancer Institute. The 5-year overall survival rate is 71% for patients with NHL. Although the etiology of NHL is unclear, several risk factors that can be involved in a greater chance of developing NHL, including demographics, environmental and therapeutic agents, genetic factors, and immune status. NHL can be further classified into subtype. To date, NHL has more than 60 subtypes, such as Burkitt lymphoma, chronic lymphocytic leukemia, extranodal marginal zone lymphoma and so on. It can also be divided into aggressive or indolent two types. Aggressive NHL is fast-growing and accounts for 60% of NHL, while indolent lymphomas are slow-growing and have fewer symptoms when diagnosed.

Fig.1 Anatomy of the lymph system, NHL usually originates in lymphoid tissues.

ADC Development for NHL

Although the outcome of patients with NHL has improved over the years, the first-line therapy, immunochemotherapy such as rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone (R-CHOP) still remains unsatisfactory in patients with high-risk disease. Besides, some intensive approaches such as high-dose chemotherapy and stem-cell transplantation, which have not presented significant beneficial and might not be tolerated by older patients. Thus, the safety profiles of new therapeutic agents are important considerations.

So far, some ADCs are under-evaluated actively in clinical trials for the NHL treatment. Totally, these ADCs include Polatuzumab vedotin (also known as RG7596 or DCDS4501A), Denintuzumab mafodotin (also known as SGN-CD19A), RG7986 (also known as DCDS0780A), AGS67E, Pinatuzumab vedotin (also known as RG7593 or DCDT2980S), Vorsetuzumab mafodotin (also known as SGN-75), Naratuximab emtansine (also known as IMGN529), ADCT-301 (also known as HuMax-TAC-PBD) and IMMU-110(Anti-CD74-DOX ADC). Take Polatuzumab vedotin as an example, it is a antibody-drug conjugate targeting CD79B and has shown significant preclinical antitumour activity. This ADC consists of the microtubule-disrupting agent monomethyl auristatin E (MMAE) conjugated to an anti-CD79B monoclonal antibody. Clinical results suggested that Polatuzumab vedotin has an acceptable safety and tolerability profile in patients with NHL.

Creative Biolabs offers a variety of ADC development services for NHL, following are some hot targets:

Fig.2 MoA: Polatuzumab vedotin (anti-CD79b ADC).

What Can We Do for You?

As the new generation of immunotherapy, ADCs are meticulously constituted bio-macromolecules with high potential in the treatment of NHL. Creative Biolabs's goal is to provide you with the most affordable and high-quality ADC construction service to ensure your satisfaction. We serve the diverse needs of our clients and we can tailor specific service packages to fit your timeline and R&D budget. Please contact us for more information and a detailed quote.

For Research Use Only. NOT FOR CLINICAL USE.